Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVERAGE-Africa: Early Treatment for Non-Severe COVID-19
NCT04920838Phase 3Unknown
- Sponsor
- ANRS
- Start
- Apr 2021
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of fluoxetine, EPI-EE, nitazoxanide, ciclesonide and telmisartan in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by ANRS. Primary endpoints: Oxygen Saturation Percentage <= 93% at 14 days and Death within 14 days. Status: unknown.
02
Drugs
fluoxetineEPI-EEnitazoxanideciclesonidetelmisartan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04920838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920838.